/L (±58).
There was no statistically significant difference in the rates of bone pain, headache, myalgia and paresthesia between the sickle cell trait and non-sickle cell trait groups (Table 2 ). In the sickle cell trait group, three donors had headache, one had bone pain and one had paresthesia. In the non-sickle cell trait group, two had headache, two had bone pain and one had myalgia. No donor in our study had chest pain, seizure, bleeding, nausea and vomiting, transfusion, infection, splenic rupture and carpal-tunnel syndrome and no deaths were reported. The mean CD34+ cell counts were 98.2 × 10 6 /L (±87.1) in the sickle cell trait group and 81.87 × 10 6 /L (±78.7) in the non-sickle cell trait control group (P = 0.81). The CD34 positive cells per kg recipient was 6.5 × 10 6 (±1.8) in the sickle cell trait group and 7.4 × 10 6 (±2.2) in the control group with no statistically significant difference (P = 0.382).
Our matched case control study demonstrated the low rates of adverse events in donors with sickle cell trait undergoing highdose G-CSF mobilization and peripheral stem cell collection. There was no difference in the rate of adverse events between the sickle cell trait and non-sickle cell trait groups and no death was reported in the study. The results are similar to the study reported by Kang et al. 3 and in another study, 4 where 10 patients with SCD were transplanted and no adverse events were observed in donors with sickle cell trait. The rate of adverse events related to PBSC mobilization was very low in our study and a number of other studies. 5 The process is very safe and findings from large registries of unrelated donors suggest the same. 5 Nevertheless, some rare complications can be serious, like seizure, splenic rupture and line thrombosis for healthy volunteer donors. The major limitation of our study is the small sample size. The adverse events were assigned retrospectively based on physicians and nursing notes, and hence, we neither could apply a consistent definition nor classify the severity of the reported complications. It is difficult to make definite conclusions on the safety of using G-CSF in this group from our study. A large number of donors with sickle cell trait are needed in the future to make such a definite conclusion. The fact that our findings are similar to the previously reported study 3 makes it more likely that these results are true. In conclusion, peripheral stem cell mobilization using G-CSF was well tolerated among the sickle cell trait donors and mobilization adverse events were not different than in non-sickle cell trait donors. Further study using a large number of sickle cell trait donors is required to conclude that there is no additional risk in the development of adverse effects during stem cell mobilization with G-CSF in this donor group.
